Portopulmonary Hypertension Before Liver Transplantation
A 60-year-old man with hepatitis C cirrhosis, cured with direct-acting antivirals, is evaluated for liver transplantation. MELD-Na is 22. He reports progressive dyspnea on exertion and has a loud pulmonic component of S2, 2+ leg edema, and JVP 12 cm. Echocardiogram shows RVSP 58 mmHg with a TR jet velocity of 3.5 m/s and a dilated right ventricle. Right heart catheterization after diuresis: mean pulmonary artery pressure 42 mmHg, pulmonary vascular resistance 5.2 Wood units, pulmonary capillary wedge pressure 11 mmHg, cardiac output 5.0 L/min, and mixed venous oxygen saturation 62%. He is on furosemide and spironolactone, with creatinine 1.3 mg/dL and sodium 132 mmol/L. He asks whether he can be listed now and what can be done to improve his candidacy.
1. How do you classify his pulmonary hypertension, and is he currently a transplant candidate? Explain the hemodynamic reasoning.
Read the worked answer
Classification. He meets the hemodynamic definition of portopulmonary hypertension: mean pulmonary artery pressure >20 mmHg, pulmonary vascular resistance >3 Wood units, and pulmonary capillary wedge pressure ≤15 mmHg, in the setting of portal hypertension. His values are mPAP 42 mmHg, PVR 5.2 Wood units, and PCWP 11 mmHg. The severity is at least moderate-to-severe because mPAP is >35 mmHg and PVR is >5 Wood units.
Candidacy. He should not be listed now. Untreated or poorly controlled portopulmonary hypertension carries a high perioperative mortality from right ventricular failure, and the risk persists even if MELD-Na is only 22. The evaluation should also exclude left heart disease, volume overload, and thromboembolic disease; the right heart catheterization already makes those less likely. Listing should be deferred until pulmonary hemodynamics improve on therapy.
2. Outline the pretransplant management and the hemodynamic targets you would use before reconsidering listing.
Read the worked answer
Pretransplant therapy. Continue diuretics with careful monitoring of renal function and electrolytes. Refer to a pulmonary hypertension center and start pulmonary vasodilator therapy, typically an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, or a prostacyclin analog; the choice depends on right ventricular function, oxygenation, and local expertise. Avoid calcium-channel blockers unless there is documented vasoreactivity.
Targets. Reassess with right heart catheterization after 3-6 months. A commonly used listing threshold is mPAP <35 mmHg and PVR <3-4 Wood units with preserved cardiac output and right ventricular function. If these targets are not achieved, transplantation remains high risk. The patient should also receive standard cirrhosis care, including variceal screening and nutrition, and be managed by a multidisciplinary team.
3. If his mPAP falls to 32 mmHg and PVR to 2.8 Wood units on therapy, what else influences whether transplantation is appropriate?
Read the worked answer
Improved hemodynamics make transplantation possible but do not guarantee a good outcome. I would reassess right ventricular function, functional status, oxygen requirement, renal function, frailty, and the ability to tolerate vasodilator therapy. Persistent severe right ventricular dysfunction, refractory hypoxemia, or intolerance of therapy would still argue against transplant. The intraoperative plan should include pulmonary artery catheter monitoring, avoidance of fluid overload, and availability of pulmonary vasodilators. MELD exception policies for portopulmonary hypertension vary and should not be assumed; the decision remains center-specific. I would also confirm that no other absolute contraindication has emerged.